Avandia is a brand name of rosiglitazone, approved by the FDA in the following formulation(s):
AVANDIA (rosiglitazone maleate - tablet; oral)
Manufacturer: SB PHARMCO
Approval date: May 25, 1999
Strength(s): EQ 2MG BASE, EQ 4MG BASE, EQ 8MG BASE [RLD]
Has a generic version of Avandia been approved?
No. There is currently no therapeutically equivalent version of Avandia available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Avandia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Novel compounds
Patent 5,002,953
Issued: March 26, 1991
Inventor(s): Hindley; Richard M.
Assignee(s): Beecham Group p.l.c.
Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
Patent expiration dates:
- September 17, 2011
✓
Patent use: TREATMENT FOR TYPE 2 DIABETES MELLITUS
✓
Drug substance
✓
Drug product
- September 17, 2011
✓
Patent use: USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
✓
Drug substance
✓
Drug product
- September 17, 2011
✓
Patent use: USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
✓
Drug substance
✓
Drug product
- March 17, 2012
✓
Pediatric exclusivity
Substituted thiazolidinedionle derivatives
Patent 5,741,803
Issued: April 21, 1998
Inventor(s): Pool; Colin Ripley & Tremper; Alan William & Brightwell; Malcolm David & Roman; Robin Sherwood
Assignee(s): SmithKline Beecham plc
##STR1## A compound of formula (I) or a tautomeric form therof and/or a pharmaceutically acceptable solvate thereof, wherein R1,A1,A2,M are as defined in the, specification. A process for preparing such a compound, a pharmaceutical composition containin such a compound and the use of such a compound for treating hyperglycemia.
Patent expiration dates:
- April 21, 2015
✓
Patent use: USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
✓
Drug substance
✓
Drug product
✓
Sponsor has requested patent be delisted
- April 21, 2015
✓
Patent use: USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
✓
Drug substance
✓
Drug product
✓
Sponsor has requested patent be delisted
- October 21, 2015
✓
Pediatric exclusivity
Compounds
Patent 6,288,095
Issued: September 11, 2001
Inventor(s): Hindley; Richard Mark & Cawthorne; Michael Antony
Assignee(s): Beecham Group p.l.c.
A method is provided for the treatment and/or prophylaxis of cardiovascular diseases or eating disorders in a human or non-human mammal, which comprises administering to a human or non-human mammal in need thereof, an effective, non-toxic amount of a compound of formula (I): ##STR1## or a tautomeric form thereof and/or a pharmaceuticlaly acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in which A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6.
Patent expiration dates:
Thiazolidinedione derivative and its use as antidiabetic
Patent 7,358,366
Issued: April 15, 2008
Inventor(s): Blackler; Paul David James & Giles; Robert Gordon & Moore; Stephen & Sasse; Michael John
Assignee(s): SmithKline Beecham p.l.c.
A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm−1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm−1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
Patent expiration dates:
- April 19, 2020
✓
Drug substance
- October 19, 2020
✓
Pediatric exclusivity
See also...
- Avandia Consumer Information (Drugs.com)
- Avandia Consumer Information (Wolters Kluwer)
- Avandia Consumer Information (Cerner Multum)
- Avandia Advanced Consumer Information (Micromedex)
- Avandia AHFS DI Monographs (ASHP)
- Rosiglitazone Consumer Information (Wolters Kluwer)
- Rosiglitazone Consumer Information (Cerner Multum)
- Rosiglitazone Advanced Consumer Information (Micromedex)
- Rosiglitazone Maleate AHFS DI Monographs (ASHP)
